Cigna Investments Inc. New bought a new position in shares of Albemarle Co. (NYSE:ALB) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,783 shares of the specialty chemicals company’s stock, valued at approximately $223,000.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Simon Quick Advisors LLC acquired a new position in shares of Albemarle in the 4th quarter valued at $32,000. CWM LLC boosted its holdings in shares of Albemarle by 84.9% in the 3rd quarter. CWM LLC now owns 501 shares of the specialty chemicals company’s stock valued at $35,000 after purchasing an additional 230 shares during the last quarter. CFM Wealth Partners LLC acquired a new position in shares of Albemarle in the 4th quarter valued at $69,000. Carroll Financial Associates Inc. boosted its holdings in shares of Albemarle by 61.8% in the 4th quarter. Carroll Financial Associates Inc. now owns 1,018 shares of the specialty chemicals company’s stock valued at $74,000 after purchasing an additional 389 shares during the last quarter. Finally, CENTRAL TRUST Co boosted its holdings in shares of Albemarle by 21.8% in the 3rd quarter. CENTRAL TRUST Co now owns 1,118 shares of the specialty chemicals company’s stock valued at $77,000 after purchasing an additional 200 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.
In other news, CFO Scott Tozier sold 2,753 shares of the firm’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $71.56, for a total value of $197,004.68. Following the transaction, the chief financial officer now owns 52,425 shares of the company’s stock, valued at approximately $3,751,533. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.02% of the company’s stock.
Shares of ALB stock opened at $89.64 on Friday. The company’s fifty day simple moving average is $78.78 and its 200-day simple moving average is $69.49. Albemarle Co. has a 52 week low of $58.63 and a 52 week high of $93.14. The company has a current ratio of 1.39, a quick ratio of 0.82 and a debt-to-equity ratio of 0.34. The company has a market cap of $9.32 billion, a PE ratio of 15.06, a P/E/G ratio of 1.82 and a beta of 1.57.
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. Its Lithium segment offers lithium compounds, including lithium carbonate, lithium hydroxide, lithium chloride, and value-added lithium specialties, as well as reagents, such as butyllithium and lithium aluminum hydride for applications in lithium batteries for consumer electronics and electric vehicles, high performance greases, thermoplastic elastomers for car tires, rubber soles, plastic bottles, catalysts for chemical reactions, organic synthesis processes, life science, pharmaceutical, and other markets.
Read More: Diversification For Individual Investors
Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.